Let's Get Started

Biotech

Patton Thomas M is Buying Cas Medical Systems Inc. (NASDAQ:CASM) Shares

Apr 4, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Cas Medical Systems Inc. (NASDAQ:CASM) reported that Patton Thomas M has picked up 1,623,389 of common stock as of 2017-04-04.

The acquisition brings the aggregate amount owned by Patton Thomas M to a total of 1,623,389 representing a 5.6% stake in the company.

For those not familiar with the company, CAS Medical Systems, Inc. is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products for patient care. The Company designs, manufactures and distributes the FORE-SIGHT and FORE-SIGHT ELITE brand tissue oximeters and sensors. It also sells various legacy products called Traditional Monitoring, which includes non-invasive blood pressure measurement technologies, neonatal medical disposables and service sales. It operates through two categories of sales: Tissue Oximetry Monitoring, which includes sales of its FORE-SIGHT tissue oximeter monitors, sensors and accessories, and Traditional Monitoring, which includes sales of its legacy products comprising the original equipment manufacturer (OEM) sales of its non-invasive blood pressure technology (MAXNIBP and MAXIQ), and monitor service and repair. The FORE-SIGHT Tissue Oximeter technology provides clinicians a non-invasive, quantitative measurement of oxygenation in cerebral tissue.

A glance at Cas Medical Systems Inc. (NASDAQ:CASM)’s key stats reveals a current market capitalization of 40.65 Million based on 28.23 Million shares outstanding and a price at last close of $1.46 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-05-28, Novelly picked up 500 at a purchase price of $1.25. This brings their total holding to 5,400 as of the date of the filing.

On the sell side, the most recent transaction saw Flynn unload 517,450 shares at a sale price of $1.46. This brings their total holding to 2,358,636.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Cas Medical Systems Inc. (NASDAQ:CASM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Catch Peregrine Pharmaceuticals (NASDAQ:PPHM) Shares on This Pullback

Catch Peregrine Pharmaceuticals (NASDAQ:PPHM) Shares on This Pullback

Apr 4, 2017

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares dipped 2.60% on Monday to $0.637 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.28 to $0.77. The company has a market cap of $184.75 million at 297.71 million shares outstanding.

Peregrine Pharmaceuticals is a biopharmaceutical company that operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.

Bavituximab, which is its lead immunotherapy candidate, is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The company’s subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

In a press release, Peregrine Pharmaceuticals announced the presentation of positive new data from the company’s ongoing collaboration with researchers from Memorial Sloan Kettering Cancer Center. This will highlight the phosphatidylserine (PS)-targeting antibodies to enhance the anti-tumor activity of adoptive T cell transfer therapy without triggering any off-target toxicities.

While adoptive T cell transfer remains one of the most exciting new approaches to treating cancer, to date the toxicity associated with the treatment has limited its potential.  We are encouraged that these study results showed that the combination of anti-PS and adoptive T cell treatment led to enhanced anti-tumor effect without any evidence of additional off-target side effects,” said Taha Merghoub, Ph.D., co-director of the Ludwig Collaborative Laboratory at MSK.  “We believe that these findings may support potential applications for this combination in solid tumors in the future.”

Cancer immunotherapy thought-leaders, Taha Merghoub, Ph.D. and Jedd D. Wolchok, M.D., Ph.D., evaluated and compared the anti-tumor activity and off-target toxicities of adoptive T cell transfer therapy in combination with either PS-targeting antibodies. Additional study results demonstrated that the PS-targeting antibodies decreased tumor-induced immunosuppression as evidenced by a decrease in immunosuppressive regulatory T cells (Tregs) and M2 macrophages, consistent with Peregrine Pharmaceuticals belief that bavituximab may modulate the immunosuppressive tumor microenvironment and enhance the activity of immunotherapy agents.

These study results provide further support for our belief that anti-PS agents such as bavituximab can play an important role as part of combination cancer treatments.  This is directly tied to the agents’ ability to modulate the tumor microenvironment to combat the immunosuppression that limits the activity of CAR T and immunotherapies,” said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine Pharmaceuticals.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

read more

Opko Health, Inc.. is Buying Vbi Vaccines Inc. (NASDAQ:VBIV) Shares

Mar 31, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Vbi Vaccines Inc. (NASDAQ:VBIV) reported that Opko Health, Inc. has picked up 6,023,014 of common stock as of 2017-03-31.

The acquisition brings the aggregate amount owned by Opko Health, Inc. to a total of 6,023,014 representing a 15.0% stake in the company.

For those not familiar with the company, VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vacis approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

A glance at Vbi Vaccines Inc. (NASDAQ:VBIV)’s key stats reveals a current market capitalization of 217.34 Million based on 40.02 Million shares outstanding and a price at last close of $5.49 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-06, Perceptive picked up 3,383,955 at a purchase price of $3.05. This brings their total holding to 6,245,725 as of the date of the filing.

On the sell side, the most recent transaction saw Mcchesney unload 1,500 shares at a sale price of $1.59. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Vbi Vaccines Inc. (NASDAQ:VBIV) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Guess Who Picked Htg Molecular Diagnostics Inc (NASDAQ:HTGM) Shares

Mar 31, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Htg Molecular Diagnostics Inc (NASDAQ:HTGM) reported that Novo A/s has picked up 1,280,185 of common stock as of 2017-03-31.

The acquisition brings the aggregate amount owned by Novo A/s to a total of 1,280,185 representing a 15.9% stake in the company.

For those not familiar with the company, HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

A glance at Htg Molecular Diagnostics Inc (NASDAQ:HTGM)’s key stats reveals a current market capitalization of 62.19 Million based on 8.05 Million shares outstanding and a price at last close of $6.92 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-08-24, Johnson picked up 1,000 at a purchase price of $5.34. This brings their total holding to 11,718 as of the date of the filing.

On the sell side, the most recent transaction saw Glaxosmithkline unload 300,000 shares at a sale price of $10.15. This brings their total holding to 792,781.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Htg Molecular Diagnostics Inc (NASDAQ:HTGM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Retractable Technologies Inc. (NYSEMKT:RVP) is Attracting Smart Money

Retractable Technologies Inc. (NYSEMKT:RVP) is Attracting Smart Money

Mar 31, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Retractable Technologies Inc. (NYSEMKT:RVP) reported that Bml Investment Partners, L.p. has picked up 1,959,059 of common stock as of 2017-03-31.

The acquisition brings the aggregate amount owned by Bml Investment Partners, L.p. to a total of 1,959,059 representing a 6.6% stake in the company.

For those not familiar with the company, Retractable Technologies, Inc. designs, develops and manufactures safety medical products for the healthcare industry. The Company markets VanishPoint and PatientSafe products. The VanishPoint products are designed specifically to prevent needle stick injuries and to prevent reuse. The VanishPoint safety products include tuberculin, insulin and allergy antigen VanishPoint syringes; 0.5mL, 1mL, 2mL, 3mL, 5mL and 10mL VanishPoint syringes, and the VanishPoint autodisable syringe. It also sells the VanishPoint intravenous catheter, the VanishPoint blood collection tube holder and the VanishPoint blood collection set. The PatientSafe syringe reduces the risk of bloodstream infections resulting from catheter hub contamination. Its PatientSafe products include 3mL, 5mL, 10mL, 20mL, 30mL and 60mL syringes, and the PatientSafe Luer cap. Its product designs include retractable needle syringe designs, retractable needle designs and retractable needle dental syringe designs.

A glance at Retractable Technologies Inc. (NYSEMKT:RVP)’s key stats reveals a current market capitalization of 31.60 Million based on 29.65 Million shares outstanding and a price at last close of $1.08 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-01-12, Shaw picked up 2,000,000 at a purchase price of $0.89. This brings their total holding to 12,065,642 as of the date of the filing.

On the sell side, the most recent transaction saw Mack unload 100 shares at a sale price of $1.42. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Retractable Technologies Inc. (NYSEMKT:RVP) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
Here’s Who Just Picked Up Depomed Inc. (NASDAQ:DEPO) Shares

Here’s Who Just Picked Up Depomed Inc. (NASDAQ:DEPO) Shares

Mar 30, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Depomed Inc. (NASDAQ:DEPO) reported that Starboard Value LP has picked up 5,490,000 of common stock as of 2017-03-30.

The acquisition brings the aggregate amount owned by Starboard Value LP to a total of 5,490,000 representing a 8.8% stake in the company.

For those not familiar with the company, Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

A glance at Depomed Inc. (NASDAQ:DEPO)’s key stats reveals a current market capitalization of 771.50 Million based on 62.10 Million shares outstanding and a price at last close of $12.82 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2013-05-10, Schoeneck picked up 25,000 at a purchase price of $5.11. This brings their total holding to 85,001 as of the date of the filing.

On the sell side, the most recent transaction saw Moretti unload 5,000 shares at a sale price of $20.84. This brings their total holding to 21,680.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Depomed Inc. (NASDAQ:DEPO) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Broadfin Capital Picked Up Alphatec Holdings Inc. (NASDAQ:ATEC) Shares

Mar 29, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alphatec Holdings Inc. (NASDAQ:ATEC) reported that has picked up 1,164,618 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 1,164,618 representing less than 9.99% stake in the company.

For those not familiar with the company, Alphatec Holdings, Inc. is a medical technology company. The Company through its subsidiary, Alphatec Spine, Inc. and its subsidiaries, designs, develops, manufactures and markets products for the surgical treatment of spine disorders. Its product portfolio and pipeline addresses the cervical, thoracolumbar and intervertebral regions of the spine and covers a range of spinal disorders and surgical procedures. Its products include Cervical and Cervico-Thoracic Products, which include Trestle Luxe Anterior Cervical Plate System and Pegasus Anchored Cervical Interbody; Thoracolumbar Fixation Products, which include Arsenal Degenerative System and OsseoScrew Spinal Fixation System; Spinal Spacers, which include Battalion Universal Spacer System and Alphatec Solus Locking ALIF Spinal Spacer; minimally invasive surgery Products, which include Illico Minimally Invasive Surgery System and BridgePoint Spinous Process Fixation System, and Biologics, which include Neocore Osteoconductive Matrix.

A glance at Alphatec Holdings Inc. (NASDAQ:ATEC)’s key stats reveals a current market capitalization of 21.89 Million based on 8.81 Million shares outstanding and a price at last close of $2.40 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-16, Cross picked up 15,000 at a purchase price of $4.25. This brings their total holding to 65,443 as of the date of the filing.

On the sell side, the most recent transaction saw Foster unload 1,033 shares at a sale price of $5.25. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alphatec Holdings Inc. (NASDAQ:ATEC) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
5am Ventures Llc. is Buying Pulmatrix Inc. (NASDAQ:PULM) Shares

5am Ventures Llc. is Buying Pulmatrix Inc. (NASDAQ:PULM) Shares

Mar 29, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Pulmatrix Inc. (NASDAQ:PULM) reported that 5am Ventures Llc. has picked up 251,188 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by 5am Ventures Llc. to a total of 251,188 representing less than 1.41% stake in the company.

For those not familiar with the company, Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.

A glance at Pulmatrix Inc. (NASDAQ:PULM)’s key stats reveals a current market capitalization of 53.11 Million based on 17.83 Million shares outstanding and a price at last close of $3.23 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2015-06-15, Mcguire picked up 1,392 at a purchase price of $6.88. This brings their total holding to 52,722 as of the date of the filing.

On the sell side, the most recent transaction saw Oculus unload 922,500 shares at a sale price of $2.75. This brings their total holding to 0.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Pulmatrix Inc. (NASDAQ:PULM) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more

Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) is Attracting Smart Money

Mar 29, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) reported that Longboard Capital Advisors, Llc. has picked up 1,312,000 of common stock as of 2017-03-29.

The acquisition brings the aggregate amount owned by Longboard Capital Advisors, Llc. to a total of 1,312,000 representing a 6.58% stake in the company.

For those not familiar with the company, Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

A glance at Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY)’s key stats reveals a current market capitalization of 85.48 Million based on 19.94 Million shares outstanding and a price at last close of $3.85 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-12-19, Lindstrom picked up 100,000 at a purchase price of $1.79. This brings their total holding to 100,000 as of the date of the filing.

On the sell side, the most recent transaction saw Miloni unload 110,000 shares at a sale price of $8.00. This brings their total holding to 468,576.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more